As we get ready for BioPharmX Corporation (NYSE:BPMX) earnings, we have an opportunity to take a quantitative approach to preparation. The company’s first numbers are slated to hit the wires after market close (confirmed) on December 31, 1969. Hence, it’s a good time to take a thorough look at the company’s historical behavior around earnings, as well as where current expectations stand for performance in the quarter.
BioPharmX Corporation (NYSE:BPMX) Historical Stock Behavior Data for Earnings Reports
According to market and research data, the company’s average earnings surprise was -9.56 percent, when looking at the prior year. Let’s look at how these four reports worked out in detail.
The company put up an EPS number of -0.09 on March 23, 2017. That topped the consensus expectation of $-0.10, representing a Negative surprise of -10.00% That report showed a top line number of $0.01M, which compares to a consensus estimate of $0.03M. In reaction, the stock dropped -10.91% on the next day. A week later, the price change was -7.27%.
The company put up an EPS number of $-0.13 on December 13, 2016. That compared with a consensus expectation of $-0.16, representing a Negative surprise -16.13%. That report also showed a top line number of $0.03M, which compares to a consensus estimate of $0.02M put out by analysts ahead of the report. That spurred a move of 30.00% a day later. Seven days after that, the stock had posted a net move of -7.50%.
If we look back at September 12, 2016, we see a company able to log an EPS print of $-0.18. That missed the projected outlook of $-0.17, handing the market a Negative surprise of -9.09%. Sales came in at $0.02M, which countered expectations of $0.05M, leading to a net move in shares of -8.22% the following day, and -4.11% seven days out.
Finally, on December 31, 1969, we saw a Negative surprise of -3.03% when the company came to the table with an EPS of $-0.17, answering analysts at $-0.17 on the bottom line. The top line hit at $0.03M (versus $0.09M).
BioPharmX Corporation (NYSE:BPMX): What’s the Word on the Street?
This time around, Q1 is expected to offer up an EPS point of $-0.07, with a range of $-0.07-$-0.07. The top line expectation range out from analysts right now is at $10k-$40k, pushing a mean of $20k.
Shares of BioPharmX Corporation (NYSE:BPMX) printed a last close of $0.83, which pushes the total market value of the company to roughly $57.19M. Where is it headed from here? It’s impossible to say, but analysts currently have a consensus 12-month target out right now at $3.00.
Looking at recent action, we’ve seen shares declined -31.96% off trailing year highs, but advance overall 1 a ytd basis. The stock has been bouncing in a recent range defined by the $0.7330-$0.8500 levels, with transactions averaging about 3,002,425 shares per day. Over about the past week, the stock has moved nearly -1.18% higher, representing a total gain of 341.54% off its 52-week low.
Finally, the summary performance stats on reporting suggest that there is roughly a 83 percent chance that the stock down in reaction to its next quarterly data peek. If we dig a bit deeper, we can see that shares of the stock saw gains about down 5 out of 6 quarters on recent record. As far as the actual results, the company has “beaten the number” at a rate of roughly 28% over its past 12 reports. On the other hand, the company swung and missed 3 times, with 1 instances of inline data. At present, the company’s stock price per share has shifted about percent since the last time it turned in a report card, when it was printing orders around $0.55/share.